Martin M Zenni
Overview
Explore the profile of Martin M Zenni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
566
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ortega-Paz L, Franchi F, Rollini F, Galli M, Been L, Ghanem G, et al.
JACC Basic Transl Sci
. 2024 Aug;
9(7):865-876.
PMID: 39170956
This prospective ex vivo and in vitro pharmacodynamic (PD)/pharmacokinetic investigation was conducted in patients with diabetes mellitus with (n = 31) and without chronic kidney disease (n = 30). PD...
2.
Ortega-Paz L, Bor W, Franchi F, van den Broek W, Rollini F, Giordano S, et al.
JACC Cardiovasc Interv
. 2024 Apr;
17(11):1356-1370.
PMID: 38597172
Background: Among patients treated with a novel oral anticoagulant (NOAC) undergoing percutaneous coronary intervention (PCI), combination therapy with clopidogrel (ie, known as dual antithrombotic therapy [DAT]) is the treatment of...
3.
Franchi F, Rollini F, Ortega-Paz L, Been L, Giordano S, Galli M, et al.
JACC Cardiovasc Interv
. 2023 Aug;
16(20):2528-2539.
PMID: 37609698
Background: A drug-drug interaction (DDI) may occur when transitioning from intravenous P2Y inhibition with cangrelor to oral P2Y inhibition with prasugrel. However, this has never been tested in patients undergoing...
4.
Ortega-Paz L, Franchi F, Rollini F, Galli M, Been L, Ghanem G, et al.
Thromb Haemost
. 2023 May;
124(3):263-273.
PMID: 37224883
Background: To date, there are no data on switching to dual pathway inhibition (DPI) patients who have completed a guideline-recommended dual antiplatelet therapy (DAPT) regimen. Objectives: To assess the feasibility...
5.
Franchi F, Ortega-Paz L, Rollini F, Galli M, Been L, Ghanem G, et al.
JACC Cardiovasc Interv
. 2022 Nov;
16(1):36-46.
PMID: 36317958
Background: There are no studies specifically designed to rule out a drug-drug interaction (DDI) when cangrelor is used among patients who have been pretreated with ticagrelor. Objectives: This study sought...
6.
Galli M, Rollini F, Been L, Zenni M, Angiolillo D, Franchi F
J Thromb Thrombolysis
. 2022 Sep;
54(3):461-469.
PMID: 36048358
Switching P2Y inhibitors is common in clinical practice. However, data on the pharmacodynamic (PD) effects of switching in clinical settings characterized by high platelet reactivity, such as diabetes mellitus (DM),...
7.
Galli M, Franchi F, Rollini F, Been L, Jaoude P, Rivas A, et al.
Eur Heart J Cardiovasc Pharmacother
. 2022 Mar;
8(7):728-737.
PMID: 35353154
Aims: Dual pathway inhibition (DPI) by adding a vascular dose of rivaroxaban to a single antiplatelet agent has emerged as a promising antithrombotic strategy. However, in most studies the antiplatelet...
8.
Galli M, Franchi F, Rollini F, Been L, Jaoude P, Rivas A, et al.
Thromb Haemost
. 2022 Jan;
122(8):1341-1351.
PMID: 34983074
Aim: Inhibition of thrombin-mediated signaling processes using a vascular dose of rivaroxaban in adjunct to antiplatelet therapy, known as dual-pathway inhibition (DPI), reduces atherothrombotic events in patients with stable atherosclerotic...
9.
Franchi F, Rollini F, Galli M, Been L, Ghanem G, Shalhoub A, et al.
JACC Cardiovasc Interv
. 2021 Nov;
14(21):2410-2412.
PMID: 34736741
No abstract available.
10.
Franchi F, Rollini F, Been L, Maaliki N, Jaoude P, Rivas A, et al.
Eur Heart J Cardiovasc Pharmacother
. 2021 Jun;
8(5):452-461.
PMID: 34114623
Aims: Patients with diabetes mellitus (DM) and chronic kidney disease (CKD) are at increased risk of atherothrombotic events. Ticagrelor reduces ischaemic events compared to clopidogrel, with the greatest risk reduction...